Switch theme
Sign up to access all valuation multiples
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
1995
103
LTM Revenue $24.8M
LTM EBITDA -$175M
$62.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lexicon Pharmaceuticals has a last 12-month revenue of $24.8M and a last 12-month EBITDA of -$175M.
In the most recent fiscal year, Lexicon Pharmaceuticals achieved revenue of $31.1M and an EBITDA of -$184M.
Lexicon Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lexicon Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $31.1M | XXX | XXX | XXX |
| Gross Profit | $0.1M | $1.1M | XXX | XXX | XXX |
| Gross Margin | 12% | 4% | XXX | XXX | XXX |
| EBITDA | -$163M | -$184M | XXX | XXX | XXX |
| EBITDA Margin | -13577% | -593% | XXX | XXX | XXX |
| Net Profit | -$102M | -$177M | XXX | XXX | XXX |
| Net Margin | -8467% | -570% | XXX | XXX | XXX |
| Net Debt | $2.2M | $77.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lexicon Pharmaceuticals's stock price is $1.
Lexicon Pharmaceuticals has current market cap of $192M, and EV of $62.0M.
See Lexicon Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $62.0M | $192M | XXX | XXX | XXX | XXX | $-0.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lexicon Pharmaceuticals has market cap of $192M and EV of $62.0M.
Lexicon Pharmaceuticals's trades at 2.5x LTM EV/Revenue multiple, and -0.4x LTM EBITDA.
Analysts estimate Lexicon Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lexicon Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $62.0M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | -0.3x | XXX | XXX | XXX |
| P/E | -1.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLexicon Pharmaceuticals's NTM/LTM revenue growth is -59%
Lexicon Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $2.2M for the same period.
Over next 12 months, Lexicon Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lexicon Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lexicon Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2481% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -593% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -652% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 272% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 732% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lexicon Pharmaceuticals acquired XXX companies to date.
Last acquisition by Lexicon Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Lexicon Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lexicon Pharmaceuticals founded? | Lexicon Pharmaceuticals was founded in 1995. |
| Where is Lexicon Pharmaceuticals headquartered? | Lexicon Pharmaceuticals is headquartered in United States of America. |
| How many employees does Lexicon Pharmaceuticals have? | As of today, Lexicon Pharmaceuticals has 103 employees. |
| Who is the CEO of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals's CEO is Dr. Michael Exton, PhD. |
| Is Lexicon Pharmaceuticals publicy listed? | Yes, Lexicon Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals trades under LXRX ticker. |
| When did Lexicon Pharmaceuticals go public? | Lexicon Pharmaceuticals went public in 2000. |
| Who are competitors of Lexicon Pharmaceuticals? | Similar companies to Lexicon Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals's current market cap is $192M |
| What is the current revenue of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals's last 12-month revenue is $24.8M. |
| What is the current EBITDA of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals's last 12-month EBITDA is -$175M. |
| What is the current EV/Revenue multiple of Lexicon Pharmaceuticals? | Current revenue multiple of Lexicon Pharmaceuticals is 2.5x. |
| What is the current EV/EBITDA multiple of Lexicon Pharmaceuticals? | Current EBITDA multiple of Lexicon Pharmaceuticals is -0.4x. |
| What is the current revenue growth of Lexicon Pharmaceuticals? | Lexicon Pharmaceuticals revenue growth between 2023 and 2024 was 2481%. |
| Is Lexicon Pharmaceuticals profitable? | Yes, Lexicon Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
